Cherisse Marcou, Ph.D., and Kristen Rasmussen, M.S., CGC, explain how Mayo Clinic Laboratories' WESPR whole exome sequencing reflex test provides cost-effective diagnosis of complex genetic conditions. Using samples and data from previous targeted gene panels, WESPR's wider net can identify undetected genetic variants.
(00:32)
Would each of you share a little bit about yourselves and your background?
(01:42)
Could you provide us with an overview of the whole exome reflexing panel?
(02:53)
Is this different from our whole exome sequencing panel and our whole exome reanalysis panel?
(04:00)
Tell us more about who benefits from this test.
(06:17)
What is the clinical utility of this testing?
(08:07)
Would you help providers understand how to go about ordering?
(11:23)
Could you tell us more about the types of variants identified by this test?
(13:39)
Based on those performance characteristics, how does our test match up to other exome tests available in the market?
(14:30)
Are there any other unique features you would like to highlight?
(15:57)
What is the turnaround time for the reflex panel?
(16:14)
Can the results from the WESPR test be reanalyzed in the future as new genetic knowledge emerges?
(16:56)
How are variants reported, especially variants of uncertain significance? And does the report include recommendations?
(19:31)
Would you summarize the benefits of the WESPR at Mayo Clinic Laboratories?
